<li id="4w4yg"></li>
<button id="4w4yg"><input id="4w4yg"></input></button>
<li id="4w4yg"></li>
  • <li id="4w4yg"><source id="4w4yg"></source></li>
  • <strike id="4w4yg"></strike>
    <strike id="4w4yg"><acronym id="4w4yg"></acronym></strike><button id="4w4yg"><dl id="4w4yg"></dl></button>
    <strike id="4w4yg"><acronym id="4w4yg"></acronym></strike>
    <bdo id="4w4yg"></bdo>
    產(chǎn)品展示 / products 您的位置:網(wǎng)站首頁 > 產(chǎn)品展示 > 細(xì)胞庫 > 細(xì)胞系 > 人非小細(xì)胞肺癌細(xì)胞NCI-H358
    人非小細(xì)胞肺癌細(xì)胞NCI-H358

    人非小細(xì)胞肺癌細(xì)胞NCI-H358

    簡要描述:青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺,在標(biāo)準(zhǔn)化細(xì)胞庫建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度,以對科研的高度嚴(yán)謹(jǐn),以嚴(yán)格的質(zhì)量控制,為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)!

    更新時間:2023-06-29

    廠商性質(zhì):生產(chǎn)廠家

    瀏覽次數(shù):671

    詳情介紹
    品牌其他品牌貨號BFN60800666
    規(guī)格T25培養(yǎng)瓶x1 1.5ml凍存管x2供貨周期現(xiàn)貨
    主要用途僅供科研應(yīng)用領(lǐng)域醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

    細(xì)胞名稱

    人非小細(xì)胞肺癌細(xì)NCI-H358                  

    img1

    貨物編碼

    BFN60800666

    產(chǎn)品規(guī)格

    T25培養(yǎng)x1

    1.5ml凍存x2

    細(xì)胞數(shù)量

    1x10^6

    1x10^6

    保存溫度

    37

    -198

    運輸方式

    常溫保溫運輸

    干冰運輸

    安全等級

    1

    用途限制

    僅供科研用途                  1類

     

    培養(yǎng)體系

    DMEM高糖培養(yǎng)基Hyclone+10%胎牛血清Gibco+1%雙抗Hyclone

    培養(yǎng)溫度

    37

    二氧化碳濃度

    5%

    簡介

    人非小細(xì)胞肺癌細(xì)NCI-H358細(xì)胞于1981年從一位開始化療之前的患者的腫瘤組織中分離建株。超微結(jié)構(gòu)研究表明細(xì)胞質(zhì)中Clara細(xì)胞的特征結(jié)構(gòu)細(xì)胞表達(dá)主要的肺表面結(jié)合蛋SP-A的蛋白RNA。不表達(dá)SP-BSP-C。他們在軟瓊脂中的克隆形成效率0.83% 

    注釋

    Part of: Cancer Cell Line Encyclopedia (CCLE) project.

    Part of: COSMIC cell lines project.

    Part of: MD Anderson Cell Lines Project.

    Part of: NCI RAS program mutant KRAS cell line panel.

    Doubling time: 38 hours (in RPMI 1640 + 10% FBS), 76 hours (in ACL-3), 60 hours (in ACL-3 + BSA) (PubMed=3940644); 38 hours (ECACC).

    Microsatellite instability: Stable (MSS) (Sanger).

    Omics: Deep exome analysis.

    Omics: Deep phosphoproteome analysis.

    Omics: Deep proteome analysis.

    Omics: Deep RNAseq analysis.

    Omics: DNA methylation analysis.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis.

    Caution: We are not certain that NCI-H358 and NCI-H358M are identical.

    Misspelling: H1358; In PubMed=1311061 table 1.

    STR信息

     Amelogenin:X,Y;CSF1PO:11,12D13S317:812;D16S539:12,13;D18S51:14;D19S433:13,14D21S11:2830;D2S1338:17,23D3S1358:14,18;D5S818:10,12;D7S820:10,11D8S1179:13,14;FGA:20,21;TH01:6;TPOX:89;vWA:17

    參考文獻(xiàn)

    PubMed=3940644

    Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.

    Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

    Cancer Res. 46:798-806(1986)

     

    PubMed=3335022

    Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

    Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

    Cancer Res. 48:589-601(1988)

     

    PubMed=2388294; DOI=10.1093/jnci/82.17.1420

    McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M., McMahon N.A., Eggleston J.C., Boyd M.R.

    Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

    J. Natl. Cancer Inst. 82:1420-1426(1990)

     

    PubMed=2386953

    Gazdar A.F., Linnoila R.I., Kurita Y., Oie H.K., Mulshine J.L., Clark J.C., Whitsett J.A.

    Peripheral airway cell differentiation in human lung cancer cell lines.

    Cancer Res. 50:5481-5487(1990)

     

    PubMed=1311061

    Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.

    p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

    Oncogene 7:171-180(1992)

     

    PubMed=1565469

    Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P., Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F., Linnoila R.I.

    Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

    Oncogene 7:743-749(1992)

     

    PubMed=8806092; DOI=10.1002/jcb.240630505

    Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

    NCI-Navy Medical Oncology Branch cell line data base.

    J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

     

    PubMed=8806101; DOI=10.1002/jcb.240630514

    Lokshin A., Levitt M.L.

    Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.

    J. Cell. Biochem. 63 Suppl. 24:186-197(1996)

     

    PubMed=9649128; DOI=10.1038/bjc.1998.361

    Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.

    Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

    Br. J. Cancer 77:2162-2170(1998)

     

    PubMed=11030152; DOI=10.1038/sj.onc.1203815

    Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.

    Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

    Oncogene 19:4632-4639(2000)

     

    PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0

    Luk C., Tsao M.-S., Bayani J., Shepherd F., Squire J.A.

    Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.

    Cancer Genet. Cytogenet. 125:87-99(2001)

     

    PubMed=12068308; DOI=10.1038/nature00766

    Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

    Mutations of the BRAF gene in human cancer.

    Nature 417:949-954(2002)

     

    PubMed=18083107; DOI=10.1016/j.cell.2007.11.025

    Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

    Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

    Cell 131:1190-1203(2007)

     

    PubMed=19472407; DOI=10.1002/humu.21028

    Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

    A gene-alteration profile of human lung cancer cell lines.

    Hum. Mutat. 30:1199-1206(2009)

     

    PubMed=20164919; DOI=10.1038/nature08768

    Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

    Signatures of mutation and selection in the cancer genome.

    Nature 463:893-898(2010)

     

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

    Cancer Res. 70:2158-2164(2010)

     

    PubMed=22460905; DOI=10.1038/nature11003

    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

    Nature 483:603-607(2012)

     

    PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112

    Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.H., Diao L., Masrorpour F., Shen L., Liu W., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.

    Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

    Cancer Discov. 2:798-811(2012)

     

    PubMed=24135919; DOI=10.1038/ncomms3617

    Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X., Nesvizhskii A.I., Chinnaiyan A.M.

    Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

    Nat. Commun. 4:2617-2617(2013)

     

    PubMed=25485619; DOI=10.1038/nbt.3080

    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

    A comprehensive transcriptional portrait of human cancer cell lines.

    Nat. Biotechnol. 33:306-312(2015)

     

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

    A landscape of pharmacogenomic interactions in cancer.

    Cell 166:740-754(2016)

     

    PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

    Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

    Characterization of human cancer cell lines by reverse-phase protein arrays.

    Cancer Cell 31:225-239(2017)

     

    PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051

    Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

    Differential effector engagement by oncogenic KRAS.

    Cell Rep. 22:1889-1902(2018)

     

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

    Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

    Cancer Res. 79:1263-1273(2019)

     

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3

    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

    Next-generation characterization of the Cancer Cell Line Encyclopedia.

    Nature 569:503-508(2019)

     

     

    驗收細(xì)胞注意事 

    1、收到人非小細(xì)胞肺癌細(xì)NCI-H358細(xì)胞,請查看瓶子是否有破裂,培養(yǎng)基是否漏出,是否渾濁,如有請盡快聯(lián)系。 

    2、收到人非小細(xì)胞肺癌細(xì)NCI-H358細(xì)胞,如包裝完好,請在顯微鏡下觀察細(xì)胞,由于運輸過程中的問題,細(xì)胞培養(yǎng)瓶中的貼壁細(xì)胞有可能從瓶壁中脫落下來,顯微鏡下觀察會出現(xiàn)細(xì)胞懸浮的情況,出現(xiàn)此狀態(tài)時,請不要打開細(xì)胞培養(yǎng)瓶,應(yīng)立即將培養(yǎng)瓶置于細(xì)胞培養(yǎng)箱里靜 3-5 小時左右,讓細(xì)胞先穩(wěn)定下,再于顯微鏡下觀察,此時多數(shù)細(xì)胞會重新貼附于瓶壁。如細(xì)胞仍不能貼壁,請用臺盼藍(lán)染色法鑒定細(xì)胞活力,如臺盼藍(lán)染色證實細(xì)胞活力正常請按懸浮細(xì)胞的方法處理 

    3、收到人非小細(xì)胞肺癌細(xì)NCI-H358細(xì)胞后,請鏡下觀察細(xì)胞,用恰當(dāng)方式處理細(xì)胞。若懸浮的細(xì)胞較多,請離心收集細(xì)胞,接種到一個新的培養(yǎng)瓶中。棄掉原液,使用新鮮配制的培養(yǎng)基,使用進(jìn)口胎牛血清。剛接到細(xì)胞,若細(xì)胞不多 血清濃度可以加 15%去培養(yǎng)。若細(xì)胞迏 80% ,血清濃度還是 10。 

    4、收到人非小細(xì)胞肺癌細(xì)NCI-H358細(xì)胞時如無異常情 ,請在顯微鏡下觀察細(xì)胞密度,如為貼壁細(xì)胞,未超80%匯合度時,將培養(yǎng)瓶中培養(yǎng)基吸出,留 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng):超 80%匯合度時,請按細(xì)胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細(xì)胞,吸出培養(yǎng)液,1000 轉(zhuǎn)/分鐘離 3 分鐘,吸出上清,管底細(xì)胞用新鮮培養(yǎng)基懸浮細(xì)胞后移回培養(yǎng)瓶 

    5、將培養(yǎng)瓶置 37培養(yǎng)箱中培養(yǎng),蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里,存放 4冰箱,以備不時之需。 

    6、24 小時后,人非小細(xì)胞肺癌細(xì)NCI-H358細(xì)胞形態(tài)已恢復(fù)并貼滿瓶壁,即可傳代。(貼壁細(xì)胞)將培養(yǎng)瓶里的培養(yǎng)基倒去, 3-5ml(以能覆蓋細(xì)胞生長面為準(zhǔn)PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化時間以具體細(xì)胞為準(zhǔn),一 1-3 分鐘,不超 5 分鐘??梢苑?/span>37培養(yǎng)箱消化。輕輕晃動瓶壁,見細(xì)胞脫落下來,加 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細(xì)胞,使之*脫落,然后將溶液吸入離心管內(nèi)離心,1000rpm/5min。棄上清,視細(xì)胞數(shù)量決定分瓶數(shù),一般一傳二,如細(xì)胞量多可一傳三,有些細(xì)胞不易傳得過稀,有些生長較快的細(xì)胞則可以多傳幾瓶,以具體細(xì)胞和經(jīng)驗為準(zhǔn)。(懸浮細(xì)胞)用移液管輕輕吹打瓶壁,直接將溶液吸入離心管離心即可。 

    7、貼壁細(xì) ,懸浮細(xì)胞。嚴(yán)格無菌操作。換液時,換新的細(xì)胞培養(yǎng)瓶和換新鮮的培養(yǎng)液,37,5%CO2 培養(yǎng)。

     

    特別提醒 原瓶中培養(yǎng)基不宜繼續(xù)使用,請更換新鮮培養(yǎng)基培養(yǎng)。



    留言框

    • 產(chǎn)品:

    • 您的單位:

    • 您的姓名:

    • 聯(lián)系電話:

    • 常用郵箱:

    • 省份:

    • 詳細(xì)地址:

    • 補充說明:

    • 驗證碼:

      請輸入計算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

    聯(lián)


    无码少妇一区二区| 人妻精品久久久久中文字幕69| 中文字幕在线亚洲精品| 无码少妇一区二区性色AV| 婷婷五月六月激情综合色中文字幕| 中中文字幕亚洲无线码| 久久精品无码专区免费东京热 | 小SAO货水好多真紧H无码视频| 最好看更新中文字幕 | 国产精品无码a∨精品| 久久精品中文无码资源站| 亚洲精品乱码久久久久久中文字幕| 国产精品亚韩精品无码a在线| 最新中文字幕av无码专区 | 亚洲乱码中文字幕综合234| 中文无码一区二区不卡αv| HEYZO无码综合国产精品| 无码一区二区三区老色鬼| 97无码人妻福利免费公开在线视频 | 色多多国产中文字幕在线| 亚洲中文字幕久久精品无码喷水 | 久久久久久久人妻无码中文字幕爆| 国产午夜精华无码网站| 无码丰满熟妇juliaann与黑人 | 亚洲中文字幕无码久久综合网| 亚洲美日韩Av中文字幕无码久久久妻妇| 日韩精品一区二区三区中文| 天堂√中文最新版在线| 中文字幕在线无码一区| 亚洲日韩VA无码中文字幕| 五十路熟妇高熟无码视频| 无码激情做a爰片毛片AV片| 无码AV动漫精品一区二区免费| 四虎成人精品国产永久免费无码| 久久久精品无码专区不卡| 亚欧无码精品无码有性视频| 亚洲成A人片在线观看无码3D | 亚洲AV中文无码乱人伦下载| 精品久久久久久无码中文字幕一区| 久久亚洲精精品中文字幕| 狠狠精品久久久无码中文字幕|